| Literature DB >> 35447555 |
Wael Zeinyeh1, Yannick J Esvan1, Béatrice Josselin2, Mathilde Defois1, Blandine Baratte2, Stefan Knapp3, Apirat Chaikuad3, Fabrice Anizon1, Francis Giraud4, Sandrine Ruchaud5, Pascale Moreau6.
Abstract
Haspin (haploid germ cell-specific nuclear protein kinase) offers a potential target for the development of new anticancer drugs. Thus, the identification of new inhibitors targeting this protein kinase is of high interest. However, Haspin inhibitors developed to date show a poor selectivity profile over other protein kinases of the human kinome. Here, we identified a new pyridoquinazoline based inhibitor (4), with excellent inhibitory activity and selectivity for Haspin (IC50 of 50 nM). We describe the structure-activity relationship study including the evaluation of this inhibitor on a large panel of 486 kinases as well as on immortalized or cancer cell lines. In addition, we determined the binding mode of analog 2a in complex with Haspin using X-ray crystallography.Entities:
Keywords: Haspin; Kinase inhibition; Pyridoquinazolines
Mesh:
Substances:
Year: 2022 PMID: 35447555 DOI: 10.1016/j.ejmech.2022.114369
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514